Double-Blind Study
Definition
A trial in which neither participants nor researchers know who gets which treatment. This removes bias in how treatment is given, data collected and results judged.
Double-Blind Study
In a double-blind study, neither the participants nor the investigators (including doctors, nurses and the people assessing outcomes) know which treatment each participant is getting. The trick is to make the treatments look the same: the active drug and the placebo (or comparator) look and feel alike and are given the same way. An independent third party, such as a trial pharmacist or an unblinded statistician, holds the randomization code and can reveal it in a medical emergency.
Double-blinding removes two major sources of bias. Blinding participants prevents the placebo effect and the behavior changes that can follow from knowing whether you are on the real drug. Blinding investigators prevents conscious or unconscious differences in how patients are treated, monitored or assessed depending on their group. Without it, investigators might give more attentive care to people on the active drug, or read unclear results more favorably for the treatment group. Either would make the drug look more effective than it is.
The Phase 2 retatrutide trials were double-blind. Matched placebo injections meant participants in every group received identical-looking injections under the skin on the same schedule. That blinding was essential to the credibility of the results, because it ensured the large weight loss and metabolic gains in the active groups could be credited to retatrutide itself, not to patient expectations or investigator behavior. Double-blinding is a standard requirement for the pivotal Phase 3 trials that will support retatrutide’s regulatory submission.